ReviewWorld journal of gastroenterology2022
Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Biological Insights into Intestinal Adaptation from Preclinical Models of Short Bowel Syndrome.Cells · 2026Review
- Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients.Journal of pediatric gastroenterology and nutrition · 2026Article
- Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW.Arquivos de gastroenterologia · 2026Article
- Effect of Recombinant Tuxtide Intervention on DSS-induced Acute UC Mouse Model.Current topics in medicinal chemistry · 2026Article
- Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues.Molecules (Basel, Switzerland) · 2025Article
- Enteroendocrine cells regulate intestinal homeostasis and epithelial function.Molecular and cellular endocrinology · 2024Review
- The Possible Involvement of Glucagon-like Peptide-2 in the Regulation of Food Intake through the Gut-Brain Axis.Nutrients · 2024Review
- Endoscopic Management of Strictures in Crohn's Disease: An Unsolved Case.Journal of clinical medicine · 2024Review
- Parenteral Nutrition, Inflammatory Bowel Disease, and Gut Barrier: An Intricate Plot.Nutrients · 2024Review
- A multicentric observational retrospective study on patients with short bowel syndrome and chronic intestinal failure who underwent intestinal transplantation in Brazil.Clinics (Sao Paulo, Brazil) · 2024Observational
- The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database.Frontiers in pharmacology · 2024Article
- Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.Journal of gastroenterology · 2023Article
- Intestinal Enteroendocrine Cells: Present and Future Druggable Targets.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short bowel syndrome (SBS) with intestinal failure (IF) is a rare but severe complication of Crohn's disease (CD), which is the most frequent benign condition that leads to SBS after repeated surgical resections, even in the era of biologics and small molecules. Glucagon-like peptide-2 analogues have been deeply studied recently for the treatment of SBS-IF. These drugs have a significant intestinotrophic effect and the potential to reduce the chronic dependence of SBS-IF patients on parenteral support or nutrition. Teduglutide has been approved for the treatment of SBS-IF, and apraglutide is currently in clinical development. The use of these drugs was examined with a focus on their use in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.